Bruix J.ANN-LII CHENGLlovet J.2021-08-312021-08-3120180168-8278https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035127979&doi=10.1016%2fj.jhep.2017.10.013&partnerID=40&md5=a9d571a06e8d25a475922377c2463d9fhttps://scholars.lib.ntu.edu.tw/handle/123456789/580079[SDGs]SDG3placebo; sorafenib; carbanilamide derivative; nicotinamide; sorafenib; cancer patient; cancer survival; comparative effectiveness; disease association; hepatitis B; Hepatitis B virus; human; Letter; liver cell carcinoma; nonhuman; priority journal; systemic therapy; liver cell carcinoma; liver tumor; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenibletter10.1016/j.jhep.2017.10.013290792872-s2.0-85035127979